Press Releases

Biocon Biologics  /  Press Releases

Biocon Biologics Refinances USD 1.1 Billion (INR 93,468 million) Long Term Debt through USD Bonds and New Syndicated Facility

  • Posted by: Biocon Biologics

Biocon Biologics Announces New Dermatology Data to Be Presented at EADV Congress 2024

  • Posted by: Biocon Biologics

Biocon Biologics Secures Market Entry for Bmab 1200, a Proposed Biosimilar to Stelara®, in Europe, UK, Canada, and Japan

  • Posted by: Biocon Biologics

Biocon Q1FY25 Revenue up 30% at Rs 4,567 Cr EBITDA up 117% at Rs 1,755 Cr Net Profit at Rs 660 Cr

  • Posted by: Biocon Biologics

Biocon Foundation and IISc organize OCTF Conference on Artificial Intelligence in Oral Cancer

  • Posted by: Biocon Biologics

Biocon Biologics Moves into New North American Headquarters in Bridgewater, New Jersey

  • Posted by: Biocon Biologics

Biocon Foundation conducts awareness session in 14 Government Schools

  • Posted by: Biocon Biologics

Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili™. Enters U.S. Ophthalmology Market

  • Posted by: Biocon Biologics

Biocon Q4FY24 Revenue at Rs 3,966 Cr, EBITDA at Rs 964 Cr; Net Profit (before exceptional items) at Rs 144 Cr

  • Posted by: Biocon Biologics

Biocon Biologics Enters a Long-term Commercial Collaboration with Eris Lifesciences to Expand Patient Access in India

  • Posted by: Biocon Biologics
Share
buy twitter followers - omegle - SOL sniper bot - marsbahis güncel giriş